Cambridge UK, July 7, 2017 – Exonate Limited were awarded the ‘One to Watch’ at the UK Business Angels Association Investment Awards last night.
The judges said: ‘Exonate is showing promise in developing revolutionary approaches to treatments for eye conditions, and has been backed by investors with deep industry knowledge.’
The award category celebrated investment in life sciences businesses, including pharmaceutical, biotechnologies, medical technologies and digital health. The shortlisted companies all demonstrated their capacity for innovation and successfully used angel investment and other relevant sources of finance to increase their potential to achieve high growth.
The awards were presented by Emma Sinclair MBE, a UNICEF ambassador and youngest person in the UK to have made a company public. Emma presented 14 awards, which celebrated the UK’s high-growth entrepreneurs and the investors that have backed them on their growth journey. The awards took place last night with a Gala dinner at The Dorchester Hotel, London, where over 300 leading innovators and investors joined to network and celebrate as the winners were announced.
About Exonate:
Exonate is a privately held, early stage, biotech, company spun out of the University of Nottingham that is focused on Vascular Endothelial Growth Factor (VEGF). The Company has grown significantly in the last year as it welcomes investment and input from an increasing global market. Exonate undertakes medicinal chemistry in laboratories in the University of New South Wales which is led by Jonathan Morris and in January 2017, the Company welcomed Dr John Kurek from new investor Uniseed to its Board of Directors. Exonate continues to be funded from the University of Nottingham and also has links with the University of Bristol. Exonate continues to have strong links with Cambridge Angels and have offices based in Cambridge, laboratories in Nottingham and collaborations with laboratories in India.
It aspires to successfully deliver medicines in areas of unmet need, such as ophthalmology, pain, nephropathy and cancer, by targeting diseases through regulation of VEGF isoforms/variants that are both protective and disease promoting. Exonate’s lead program is focused on wet Age-Related Macular Degeneration, known as wet AMD, which is the leading cause of vision loss in people aged 60 and older. The Company is founded on scientific excellence with strong links to Prof. David Bates and his lab at Nottingham University specialising in the biology and biochemical pathways of VEGF splice variants.
Exonate is led by an experienced, international management team that has worked together previously, successfully raising capital for start-ups and early stage companies over many years. Management has cross-disciplinary experience in medicine, finance, drug development and the pharmaceutical and biotech industries. CEO Catherine Beech, OBE, has over 25 years biotech/pharma experience including 12 years in big pharma leading development programs in cardiovascular, Parkinson’s disease and HIV. Exonate is her 4th role as CEO of an emerging biotech company and she also has extensive experience as a non-executive board director.
Please contact Louise Shave at Exonate for further information +44 (0)1223 437042 louise.shave@exonate.com